Cargando…
Current and Emerging Targets in Immunotherapy for Osteosarcoma
Osteosarcoma is the most common primary malignancy of bone. Although outcomes of patients with osteosarcoma have improved since the introduction of chemotherapy, outcomes of metastatic or unresectable osteosarcomas are still unsatisfactory. To improve osteosarcoma outcomes, the development of novel...
Autores principales: | Miwa, Shinji, Shirai, Toshiharu, Yamamoto, Norio, Hayashi, Katsuhiro, Takeuchi, Akihiko, Igarashi, Kentaro, Tsuchiya, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332920/ https://www.ncbi.nlm.nih.gov/pubmed/30693030 http://dx.doi.org/10.1155/2019/7035045 |
Ejemplares similares
-
Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma
por: Miwa, Shinji, et al.
Publicado: (2022) -
Therapeutic Targets for Bone and Soft-Tissue Sarcomas
por: Miwa, Shinji, et al.
Publicado: (2019) -
Prognostic Value of Histological Response to Chemotherapy in Osteosarcoma Patients Receiving Tumor-Bearing Frozen Autograft
por: Miwa, Shinji, et al.
Publicado: (2013) -
Prognostic Value of Radiological Response to Chemotherapy in Patients with Osteosarcoma
por: Miwa, Shinji, et al.
Publicado: (2013) -
Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma
por: Miwa, Shinji, et al.
Publicado: (2020)